122 related articles for article (PubMed ID: 6119817)
1. Kinetics of uptake and biliary excretion of benzo(alpha)pyrene and mutagenic metabolites in isolated perfused rat liver.
Forti GC; Trieff NM
Teratog Carcinog Mutagen; 1980; 1(3):269-82. PubMed ID: 6119817
[TBL] [Abstract][Full Text] [Related]
2. Characterization of mutagenic glucuronide formation from benzo(a)pyrene in the nonrecirculating perfused rat liver.
Kari FW; Kauffman FC; Thurman RG
Cancer Res; 1984 Nov; 44(11):5073-8. PubMed ID: 6488167
[TBL] [Abstract][Full Text] [Related]
3. Mutagenic activity of biliary metabolites of 6-hydroxymethylbenzo[a]pyrene.
Hughes MF; Kadry AR; Gairola CG; Flesher JW
Mutat Res; 1986 Apr; 173(4):251-6. PubMed ID: 3513004
[TBL] [Abstract][Full Text] [Related]
4. The formation of genotoxic metabolites of benzo[a]pyrene by the isolated perfused rat liver, as detected by the bioluminescence test.
Ben-Itzhak J; Levi BZ; Shor R; Lanir A; Bassan HM; Ulitzur S
Mutat Res; 1985 Jun; 147(3):107-12. PubMed ID: 4000152
[TBL] [Abstract][Full Text] [Related]
5. Mutagenicity and in vivo disposition of biliary metabolites of benzo(a)pyrene.
Chipman JK; Millburn P; Brooks TM
Toxicol Lett; 1983 Jul; 17(3-4):233-40. PubMed ID: 6312638
[TBL] [Abstract][Full Text] [Related]
6. Effect of bile salts on rates of formation, accumulation, and export of mutagenic metabolites from benzo(a)pyrene produced by the perfused rat liver.
Kari FW; Kauffman FC; Thurman RG
Cancer Res; 1985 Apr; 45(4):1621-7. PubMed ID: 3978630
[TBL] [Abstract][Full Text] [Related]
7. Systemic excretion of benzo(a)pyrene in the control and microsomally induced rat: the influence of plasma lipoproteins and albumin as carrier molecules.
Shu HP; Bymun EN
Cancer Res; 1983 Feb; 43(2):485-90. PubMed ID: 6293698
[TBL] [Abstract][Full Text] [Related]
8. Release of mutagenic metabolites of benzo[a]pyrene from the perfused rat liver after inhibition of glucuronidation and sulfation by salicylamide.
Bock KW; Bock-Hennig BS; Lilienblum W; Volp RF
Chem Biol Interact; 1981 Aug; 36(2):167-77. PubMed ID: 6268312
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activation to a mutagen of 3-hydroxy-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene, a secondary metabolite of benzo[a]pyrene.
Glatt H; Seidel A; Ribeiro O; Kirkby C; Hirom P; Oesch F
Carcinogenesis; 1987 Nov; 8(11):1621-7. PubMed ID: 3311446
[TBL] [Abstract][Full Text] [Related]
10. Biliary excretion, systemic availability and reactivity of metabolites following intraportal infusion of [3H]benzo[a]pyrene in the rat.
Chipman JK; Frost GS; Hirom PC; Millburn P
Carcinogenesis; 1981; 2(8):741-5. PubMed ID: 6269773
[TBL] [Abstract][Full Text] [Related]
11. Uptake and excretion of benzo[a]pyrene and its metabolites by the rat pancreas.
Iqbal ZM; Yoshida A; Epstein SS
Drug Metab Dispos; 1979; 7(1):44-8. PubMed ID: 35326
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of benzo[a]pyrene in the perfused rat liver: factors affecting the release of phenolic metabolites into the bile and perfusate.
Sweeny DJ; Reinke LA
Carcinogenesis; 1987 Jun; 8(6):779-83. PubMed ID: 3608074
[TBL] [Abstract][Full Text] [Related]
13. Formation of mutagenic metabolites from benzo(a)pyrene and 2-aminoanthracene by the s-9 fraction from the liver of the Northern pike (Esox lucius): inducibility with 3-methylcholanthrene and correlation with benzo[a]pyrene monooxygenase activity.
Balk L; Depierre JW; Sundvall A; Rannug U
Chem Biol Interact; 1982 Jul; 41(1):1-13. PubMed ID: 6284388
[TBL] [Abstract][Full Text] [Related]
14. Reduced cholestatic potency of taurolithocholate during backward perfusion of the rat liver.
Baumgartner U; Hardison WG; Miyai K
Lab Invest; 1987 Jun; 56(6):576-82. PubMed ID: 3599905
[TBL] [Abstract][Full Text] [Related]
15. Metabolic inactivation of mutagenic benzo(a)pyrene metabolites: significance to carcinogenicity and implications for in vitro tests.
Glatt HR; Platt KL; Vogel K; Bücker M; Billings R; Oesch F
Dev Toxicol Environ Sci; 1980; 8():181-6. PubMed ID: 6273103
[No Abstract] [Full Text] [Related]
16. A comparison of avian and rodent S-9 liver homogenates in the Ames test.
Rosanoff KA; Jones DH; Sawyer TW
Res Commun Chem Pathol Pharmacol; 1984 Apr; 44(1):131-9. PubMed ID: 6328598
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and mutagenicity of dibenzo[a,e]pyrene and the very potent environmental carcinogen dibenzo[a,l]pyrene.
Devanesan PD; Cremonesi P; Nunnally JE; Rogan EG; Cavalieri EL
Chem Res Toxicol; 1990; 3(6):580-6. PubMed ID: 2103330
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vitro mutagenicity and metabolism of dimethylnitrosamine and benzo[a]pyrene in tissues from inbred mice treated with phenobarbital, 3-methylcholanthrene or polychlorinated biphenyls.
Hutton JJ; Meier J; Hackney C
Mutat Res; 1979 Jan; 66(1):75-94. PubMed ID: 106274
[TBL] [Abstract][Full Text] [Related]
19. Mutagenicity and metabolism of dimethylnitrosamine and benzo[alpha]pyrene in tissue homogenates from inbred Syrian hamsters treated with phenobarbital, 3-methylcholanthrene or polychlorinated biphenyls.
Hutton JJ; Hackney C; Meier J
Mutat Res; 1979 Dec; 64(6):363-77. PubMed ID: 118380
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and excretion of benzo(a)pyrene 4,5-oxide by the isolated perfused rat liver.
Smith BR; Bend JR
Cancer Res; 1979 Jun; 39(6 Pt 1):2051-6. PubMed ID: 445404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
